共 12 条
[1]
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Frick MH,Elo O,Haapa K,et al. The New England Journal of Medicine . 1987
[2]
Associations be- tween lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Syvanna M,Nieminen MS,Frick MH,et al. Circulation . 1998
[3]
Mechanism of actionof fibrates on lipid and lipoprotein metabolism. Staels B,Datlongeville J,Auwerx J,et al. Circulation . 1998
[4]
Triglyceride concentration and ischemic heart disease.an eight-year follow-up in the Copenhagen male study. Jeppesen J,Hein HO,Saudicani P,et al. Circulation . 1998
[5]
Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Frost PH,Havel RJ. The American Journal of Cardiology . 1998
[6]
Fibrates and statins in the treatment of hyperlipi-daemia: an appraisal of their efficacy and safety. Shepherd J. European Heart Journal . 1995
[7]
Micronised fenofibrate.a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Adkins JC,Faulds D. Drugs . 1997
[8]
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fruchart JC,Brewer HB,Leitersdorf E,et al. The American Journal of Cardiology . 1998
[9]
Normal triglyceride levels and coronary artery disease events: the Baltimore coronary observational long-term study. Miller M,Seidler A,Moalemi A,et al. Journal of the American College of Cardiology . 1998
[10]
Atherogenicity of triglyceride-rich lipoproteins. Krauss RM. The American Journal of Cardiology . 1998